<DOC>
	<DOCNO>NCT02407990</DOCNO>
	<brief_summary>This study evaluate safety , tolerability , pharmacokinetic profile treatment effect new drug know BGB-A317 patient advance tumor .</brief_summary>
	<brief_title>Study Safety , Pharmacokinetics Antitumor Activities BGB-A317 Subjects With Advanced Tumors</brief_title>
	<detailed_description />
	<criteria>1 . Subjects must histologically cytologically confirm advanced metastatic tumor effective standard therapy available . 2 . Subjects previously treat brain metastasis ( e ) asymptomatic radiographically/clinically stable require steroid medication 4 week prior enrollment permit . 3 . Subjects must archival tumor tissue agree tumor biopsy analysis predictive biomarkers PDL1 . ( Fresh tumor biopsy strongly recommend baseline biomarker analysis subject readily accessible tumor lesion consent biopsy . ) 4 . Subjects must measurable disease define per RECIST Version 1.1 . 5 . Male female ≥18 year age day sign informed consent . 6 . Eastern Cooperative Oncology Group ( ECOG ) performance status ≤1 . 7 . Subjects must adequate organ function indicate follow laboratory value . Absolute neutrophil count ( ANC ) ≥1,500 /mL Platelets ≥100,000 / mL Hemoglobin ≥9 g/dL ≥5.6 mmol/L without qualification Serum creatinine ≤1.5 X upper limit normal ( ULN ) Serum total bilirubin ≤ 1.5 X ULN AST ( SGOT ) ALT ( SGPT ) ≤ 2.5 X ULN OR ≤ 5 X ULN patient liver metastases International Normalized Ratio ( INR ) Prothrombin Time ( PT ) ≤1.5 X ULN Activated Partial Thromboplastin Time ( aPTT ) ≤1.5 X ULN 8 . Subjects voluntarily agree participate give write informed consent . 9 . Female subject eligible enter participate study Non childbearing potential ( i.e. , physiologically incapable become pregnant ) , include female Has hysterectomy . Has bilateral oophorectomy ( ovariectomy ) . Has bilateral tubal ligation . Is post menopausal ( total cessation menses ≥1 year ) . Childbearing potential , negative serum pregnancy test screening ( within 7 day first investigational product administration ) , use adequate contraception study entry throughout study 90 day last investigational product administration . Adequate contraception , use consistently accordance product label instruction physician , define follow : Vasectomized partner sterile prior female subject 's entry sole sexual partner female . Any intrauterine device document failure rate le 1 % per year . Double barrier contraception define condom spermicidal jelly , foam , suppository , film ; OR diaphragm spermicide ; OR male condom diaphragm . Not breast feed . 10 . Male subject eligible enter participate study vasectomize agree use contraception study treatment period least 180 day last dose study drug 1 . History severe hypersensitivity reaction mAbs . 2 . Prior malignancy active within previous 2 year except tumor patient enrol study , locally curable cancer apparently cure , basal squamous cell skin cancer , superficial bladder cancer carcinoma situ cervix breast . 3 . Prior therapy target PD1 PDL1 . 4 . Subjects fail meet enrollment criterion PD1 PDL1 trial solely due low negative predictive biomarkers . 5 . Subjects active autoimmune disease history autoimmune disease exclude . 6 . Subjects exclude condition require systemic treatment either corticosteroid ( &gt; 10 mg daily prednisone equivalent ) immunosuppressive medication within 14 day study drug administration . 7 . Has history interstitial lung disease noninfectious pneumonitis except induced radiation therapies.. 8 . Known history Human Immunodeficiency Virus ; 9 . Active infection require therapy , positive test Hepatitis B surface antigen Hepatitis C ribonucleic acid ( RNA ) ; 10 . Underlying medical condition , Investigator 's opinion , make administration study drug hazardous obscure interpretation toxicity determination adverse event ; 11 . Prior chemotherapy , radiotherapy , immunotherapy investigational therapy use control cancer must complete least 4 week least 5 halflives ( whichever short ) study drug administration , adverse event either return baseline stabilize . 12 . Use vaccine infectious disease ( e.g. , influenza , varicella , etc . ) within 4 week ( 28 day ) initiation study therapy 60 day last administration study medication .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>